Reflecting on a highly successful UEG Week 2016
With a comprehensive range of captivating new research and over 13,300 delegates in attendance, UEG Week 2016 in Vienna was a huge success in advancing the path of world-class digestive health research and is now recognised as one of Europe’s top ﬁve medical congresses. The Opening Plenary Session provided a superb overview of the most exciting developments in gastroenterology, endoscopy and hepatology in 2016, which included advancements in inﬂammatory bowel disease and coeliac disease, as well as highlights of the best scientiﬁc abstracts submitted to the congress. Among these abstracts included research outlining how gut microbial proﬁles could help to predict patient responsiveness to a low-FODMAP diet, oﬀering new hope for irritable bowel syndrome suﬀerers. A new advancement in gastrointestinal cancer imaging was also presented during the Opening Plenary. The technique involves using a standard endoscopy system with a novel set of camera ﬁlters, increasing the number of colours that can be visualised during endoscopy from three to over 50. This approach, developing the capabilities of hyperspectral imaging, could help improve the ability to detect abnormal cells in the lining of the gut.
United European Gastroenterology Journal 2016, Vol. 4(6) 812 ! Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2050640616679916 ueg.sagepub.com
One of the most popular topics during the week focused on non-coeliac gluten sensitivity. Here, amylase-trypsin inhibitors – a group of proteins found in wheat – were shown to activate an immune response in the gut that can then spread to other tissues in the body, such as the kidneys, spleen and brain, triggering the inﬂammation of chronic health conditions including multiple sclerosis, asthma and rheumatoid arthritis. Inﬂammatory bowel disease featured prominently at UEG Week 2016, including: a call for greater attention on, and funding for, paediatric IBD drug research and transition services; a one-day symposium on ‘Advances in Clinical Gastroenterology and Hepatology for Inﬂammatory Bowel Disease’; and the presentation of the eagerly-anticipated NOR-SWITCH study, demonstrating that a switch from INX to CT-P13 was not inferior to continued treatment with INX for patients with Crohn’s disease and ulcerative colitis. The NORSWITCH ﬁndings, presented during the most wellattended late-breaking abstract session at UEG Week, have the potential to signiﬁcantly inﬂuence how medicines are used around the world. To read more highlights of UEG Week 2016 visit: https://www.ueg.eu/week/past-future/ueg-week-2016/